Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:679463.
doi: 10.1155/2013/679463. Epub 2013 Nov 6.

Rapid identification of aldose reductase inhibitory compounds from Perilla frutescens

Affiliations

Rapid identification of aldose reductase inhibitory compounds from Perilla frutescens

Ji Hun Paek et al. Biomed Res Int. 2013.

Abstract

The ethyl acetate (EtOAc) soluble fraction of methanol extracts of Perilla frutescens (P. frutescens) inhibits aldose reductase (AR), the key enzyme in the polyol pathway. Our investigation of inhibitory compounds from the EtOAc soluble fraction of P. frutescens was followed by identification of the inhibitory compounds by a combination of HPLC microfractionation and a 96-well enzyme assay. This allowed the biological activities to be efficiently matched with selected HPLC peaks. Structural analyses of the active compounds were performed by LC-MS(n). The main AR inhibiting compounds were tentatively identified as chlorogenic acid and rosmarinic acid by LC-MS(n). A two-step high speed counter current chromatography (HSCCC) isolation method was developed with a solvent system of n-hexane-ethyl acetate-methanol-water at 1.5:5:1:5, v/v and 3:7:5:5, v/v. The chemical structures of the isolated compounds were determined by (1)H- and (13)C-nuclear magnetic resonance spectrometry (NMR). The main compounds inhibiting AR in the EtOAc fraction of methanol extracts of P. frutescens were identified as chlorogenic acid (2) (IC50 = 3.16 μ M), rosmarinic acid (4) (IC50 = 2.77 μ M), luteolin (5) (IC50 = 6.34 μ M), and methyl rosmarinic acid (6) (IC50 = 4.03 μ M).

PubMed Disclaimer

Figures

Figure 1
Figure 1
HPLC chromatogram (a) and active profile (b) of the HPLC microfractionated of EtOAc soluble fraction of P. frutescens for rAR inhibition in 96-well plate.
Figure 2
Figure 2
HSCCC separation of the EtOAc soluble fraction from the leaves of P. frutescens. Solvent system: n-hexane-ethyl acetate-methanol-water (1.5 : 5 : 1 : 5, v/v); flow-rate, 5.0 mL/min; revolution speed, 400 rpm; sample size, 4.0 g; injection volume, 50 mL; detection wavelength, 280 nm; stationary phase retention, 56%. Peaks I, II, III, and IV in the HSCCC chromatogram correspond to compounds 3, 1, 2, and 4, respectively.
Figure 3
Figure 3
HSCCC chromatogram of P. frutescens after HSCCC separation. Solvent system: n-hexane-ethyl acetate-methanol-water (3 : 7 : 5 : 5, v/v); flow rate, 5.0 mL/min; revolution speed, 400 rpm; sample size, 1.2 g; injection volume, 50 mL; detection wavelength, 280 nm; stationary phase retention, 53%. Peaks V and VI in the HSCCC chromatogram correspond to compounds 6 and 5, respectively.
Figure 4
Figure 4
HPLC analysis of compounds 16 separated by HSCCC. Conditions: column, Eclipse SB-C18 Rapid Resolution column (150 × 4.6 mm, 5 μm, Agilent); column temperature, 30°C; mobile phase, 0.1% TFA (solvent A) and acetonitrile (solvent B); HPLC analysis, linear gradient from 7.5 to 55% B (0–40 min). Flow rate, 0.7 mL/min; detection, photodiode array detector; injection volume, 10 μL.
Figure 5
Figure 5
Main correlation HMBC for 6.

Similar articles

Cited by

References

    1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820. - PubMed
    1. Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opinion on Investigational Drugs. 1999;8(12):2095–2119. - PubMed
    1. Tomlinson DR, Stevens EJ, Diemel LT. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends in Pharmacological Sciences. 1994;15(8):293–297. - PubMed
    1. Engerman RL, Kern TS. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes. 1993;42(6):820–825. - PubMed
    1. Bhatnagar A, Srivastava SK. Aldose reductase: congenial and injurious profiles of an enigmatic enzyme. Biochemical Medicine and Metabolic Biology. 1992;48(2):91–121. - PubMed

Publication types

LinkOut - more resources